Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
about
Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell TransplantationDeletion of TXNIP Mitigates High-Fat Diet-Impaired Angiogenesis and Prevents Inflammation in a Mouse Model of Critical Limb Ischemia.Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma.Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance.VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment.Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice.VEGF as a potential target in lung cancer.The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells.Enhanced glioma-targeting and stability of LGICP peptide coupled with stabilized peptide DA7R.Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer LookCurcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors
P2860
Q37442586-21388E44-D486-4CC6-A740-BC3A460C9EA0Q37687310-23A6F53E-D383-4425-A527-1480AF5D27AAQ41313323-A640EB01-CED0-424E-B5D5-D94D5A54108BQ41662846-DD4B7F20-51E1-424A-A476-8A332448C742Q42371626-90C0CDB6-D33F-48AB-951B-46EE8E36997FQ47098476-F74CD8A1-3D92-48B3-8943-5FCF96FD14E9Q47733010-73159990-0108-4937-9322-B10B31F4C20DQ47845243-B93D861F-5D59-41A0-ABD6-C2C87F8A8DB3Q47918409-285017FA-773C-4D6F-897C-B38FF8FC47ECQ50116329-BA44DAEA-FEFB-4AC8-A3C9-AB07597999DFQ55321973-36989442-8EB0-4CA1-B97F-8E81536B3FEDQ58122645-1F9B0631-CAE1-4575-B990-93B1A7A752B5Q58772394-60D30D0A-0CBB-46BE-87F6-E7593764D30A
P2860
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@ast
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@en
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@nl
type
label
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@ast
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@en
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@nl
prefLabel
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@ast
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@en
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@nl
P2093
P1476
Antagonist antibodies to vascu ...... R-2) as anti-angiogenic agents
@en
P2093
Beverly L Falcon
Bronislaw Pytowski
Mark T Uhlik
Sudhakar Chintharlapalli
P304
P356
10.1016/J.PHARMTHERA.2016.06.001
P407
P577
2016-08-01T00:00:00Z